Skip to content
Menu

Hemab Therapeutics Holdings, Inc. COAG

Full chart Compare
Set alert

Price alert · COAG

All alert types
39.29 USD -0.57 (-1.43%)

Regular-session close

39.29 0.00 0.00%

After hours · Nov 20, 4:01 PM ET

38.77 Day range 40.19
24.98 52-week range 54.94
YTD
+15.56%
1 year
+15.56%

 

No chart data for this range yet.
Market cap
1.84B
EPS (ttm)
-3.55
Shares out
46.73M
Forward P/E
-14.82
YTD return
+15.56%
1-year return
+15.56%
50-day average
36.72
200-day average
37.26
Enterprise value
1.43B
Volume
347.02K
Avg volume
496.66K
Open
39.50
Previous close
39.86
Day's range
38.77 – 40.19
52-week range
24.98 – 54.94
Analysts
Strong Buy
Price target
63.00 (+60.3%)
Earnings date
Feb 9, 2027

Key statistics

Price / book
4.28
Total cash
430.24M
Total debt
965.00K

Fundamental scorecard

3 of 25 checks passed on COAG’s reported financials

ValueGrowthProfitabilityHealthDividend

3of 25 checks passed

  • Value 0 of 5
  • Growth No data
  • Profitability No data
  • Financial health 3 of 5
  • Dividend No data

Statements to Sep 30, 2026.

Financials — quick view

All financials
COAG Revenue — quarterly 0
COAG Net income — quarterly -27.30M
COAG EPS — quarterly -0.58

Earnings

COAG recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Feb 9, 2027Dec 30, 2026-0.61———
Nov 10, 2026Sep 30, 2026-0.50194-0.58-0.08-15.55%
Aug 11, 2026Jun 30, 2026-0.7325-0.80-0.07-9.22%
May 21, 2026Mar 31, 2026-23.25-23.98-0.73-3.16%

Upgrades / downgrades

COAG analyst upgrades and downgrades
DateFirmActionFromTo
Nov 9, 2026LifeSci Capitalinit—Outperform
Oct 15, 2026JP Morganinit—Overweight
Oct 12, 2026Rodman & Renshawinit—Buy
Aug 12, 2026WedbushmainOutperformOutperform
Aug 11, 2026HC Wainwright & Co.mainBuyBuy
Jul 13, 2026JefferiesmainBuyBuy

About Hemab Therapeutics Holdings, Inc.

Hemab Therapeutics Holdings, Inc. operates as a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience in United States of America and Denmark. Its products includes (HMB-001), is a bispecific antibody currently in Phase 1/2 clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Phase 2 clinical development for the prophylactic treatment of Factor VII deficiency; and second clinical-stage asset, HMB-002, is a monovalent antibody in Phase 1/2 clinical development for the subcutaneous prophylactic treatment of Von Willebrand disease. It also advances multiple preclinical and discovery-stage assets. The company was founded in 2020 and is based in Cambridge, Massachusetts.

Sector
Healthcare
Industry
Biotechnology
Country
United States
Website
hemab.com

News

Your note

Sign in to keep a note on COAG — it syncs with the Stock Master app.

Insider holders

COAG insider holders
InsiderRelationLatest transactionDateShares held
MARAGANORE JOHN MDirectorConversion of Exercise of derivative securityMay 3, 202635,948
NOVO HOLDINGS A/SBeneficial Owner of more than 10% of a Class of SecurityConversion of Exercise of derivative securityMay 3, 20264,180,550
RA CAPITAL HEALTHCARE FUND,L.P.Beneficial Owner of more than 10% of a Class of SecurityPurchaseMay 11, 20260
RA CAPITAL MANAGEMENT, L.P.Beneficial Owner of more than 10% of a Class of SecurityPurchaseJun 15, 20260

Institution ownership

COAG institution ownership
Holder% heldSharesValueReported
RA Capital Management, L.P.16.71%7,808,627306.80MSep 29, 2026
Novo Holdings A/S8.95%4,180,550164.25MSep 29, 2026
FMR, LLC7.97%3,722,599146.26MSep 29, 2026
Capital International Investors7.71%3,601,463141.50MSep 29, 2026
Deep Track Capital, Lp7.68%3,587,796140.96MSep 29, 2026
Siren, L.L.C.5.06%2,366,23592.97MSep 29, 2026

Fund ownership

COAG fund ownership
Holder% heldSharesValueReported
SmallCap World Fund Inc7.50%3,506,543137.77MSep 29, 2026
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund1.19%555,54321.83MJun 29, 2026
JPMorgan Trust II-JPMorgan Small Cap Growth Fund1.14%531,38220.88MJun 29, 2026
Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund1.12%523,85320.58MSep 29, 2026
SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF1.10%514,85820.23MSep 29, 2026
iShares Trust-iShares Russell 2000 ETF1.08%506,79119.91MSep 29, 2026